A Phase 2 interventional study of Lavender Oil and Palmitoylethanolamide (PEA) in Sleep Disorder (Disorder), Stress and Anxiety, sponsored by RDC Clinical Pty Ltd. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by RDC Clinical Pty Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Sleep Wake Disorders with a site in Australia — 5 open to participants now, 6 under way, 4 of them phase 3. Sleep Wake Disorders · Australia.
Among the 18 studies in Sleep Wake Disorders with a site in Australia, this one is the 4th largest by planned enrollment, is one of 4 that started in 2026, is one of 4 in phase 2, and was the 15th registered.
747 studies on the registry are indexed under Sleep Wake Disorders; 182 are open to participants now.
Browse Sleep Wake Disorders studies →5 of the 18 studies in Sleep Wake Disorders with a site in Australia are open now. Recruiting first, the newest first:
Alkermes, Inc. · Sites in Australia, United States, Belgium and 10 more countries
Ages 18–70
Alkermes, Inc. · Sites in Australia, United States, Belgium and 11 more countries
Ages 18–70
Alkermes, Inc. · Sites in Australia, United States, Belgium and 12 more countries
Ages 18–70
Alkermes, Inc. · Sites in Australia, United States, Belgium and 5 more countries
Ages 18–70
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 114 Sleep Wake Disorders studies recruiting now, 39 (34%) set no upper age limit and 54 (47%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 5 · Phase 4 2
First in 2009; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 66 across 531 interventional studies indexed under Sleep Wake Disorders.
Median enrollment 131 across the 18 interventional studies. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 18 have an industry lead sponsor. The 10 most frequent:
RDC Clinical Pty Ltd is the lead sponsor of 34 studies on the registry; 8 are open to participants now.
RDC Clinical Pty Ltd has 1 study filed under Sleep Wake Disorders — fewer than ten, so there is no comparison to draw.
5 of the studies in Sleep Wake Disorders with a site in Australia that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07502443Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2 | 2027-05 |
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT07540897Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304) | 2027-06 |
| NCT06843590Alkermes, Inc.A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | 2026-11 |
| NCT07315516RDC Clinical Pty LtdSleep and Stress Study | 2027-02 |
Add all 5 to your calendar (.ics) → With an account.
Among the 18 studies in Sleep Wake Disorders with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if natural supplements (lavender oil, PEA, and OEA) work to improve sleep and reduce stress in adults with moderate stress levels and sleep difficulties. It will also learn about the safety of these natural supplements.
The main questions it aims to answer are:
Researchers will compare three active treatment groups (lavender oil, PEA, Trpti which contains OEA) to a placebo (a look-alike capsule that contains no active ingredients) to see if these natural supplements work to improve sleep and reduce stress.
Participants will take 1 capsule (either active supplement or placebo) every day for 8 weeks and attend 2 clinic visits with a phone check in in between.
The Effects of Natural Bioactive Compounds on Sleep and Stress: A Randomized Double-Blind Placebo-Controlled Trial This four-arm, parallel-group trial evaluates bioactive compounds targeting stress-sleep pathophysiology (lavender oil, PEA, and OEA). The 8-week intervention employs validated psychometric instruments alongside salivary biomarkers providing objective HPA axis and circadian rhythm assessment. The trial enrolls 240 participants (60 per arm) with moderate stress (PSS ≥14) and sleep complaints.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Agree to not participate in another clinical trial during the study period.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
85mg CPO Lavender oil will be administered daily, This will be taken as a capsule, 1 capsule daily for 57 days.
Dietary Supplement: Lavender Oil
75mg Levagen+ PEA will be administered daily, This will be taken as a capsule, 1 capsule daily for 57 days.
Dietary Supplement: Palmitoylethanolamide (PEA)
150mg Trpti OEA will be administered daily, This will be taken as a capsule, 1 capsule daily for 57 days.
Dietary Supplement: Oleoylethanolamide
A placebo capsule containing microcrystalline cellulose will be taken daily, 1 capsule will be taken each day for 57 days.
Other: Placebo
85mg CPO Lavender oil will be administered daily. This will be taken as a capsule, 1 capsule daily for 57 days.
Also known as: CPO Lavender oil
75mg Levagen+ PEA will be administered daily. This will be taken as a capsule, 1 capsule daily for 57 days.
Also known as: Levagen+
150mg Trpti OEA will be administered daily. This will be taken as a capsule, 1 capsule daily for 57 days
Also known as: Trpti
A placebo capsule containing microcrystalline cellulose will be taken daily, 1 capsule will be taken each day for 57 days.
Perceived stress via Perceived Stress Scale (PSS)
Change from baseline to the end of the study period in Perceived stress via Perceived Stress Scale (PSS). The Perceived Stress Scale is a self-reported tool for measuring psychological stress. A total PSS-10 score from 0 to 40 is presented, with higher scores representing higher levels of stress.
Time frame: Day 1 to day 57
Anxiety via Beck Anxiety Inventory (BAI)
Change from baseline to the end of the study period in Anxiety via Beck Anxiety Inventory (BAI). The BAI is a 21-item self-report questionnaire evaluating anxiety symptoms, rated on a 4-point scale.
Time frame: Day 1 to day 57
Sleep quality
Change from baseline to the end of the study period in Sleep quality. This will be measured via Pittsburgh Sleep Quality Index (PSQI) and Consensus Sleep Diary. The PSQI is a self-report questionnaire used to evaluate overall sleep quality. Each of the 19 items belongs to one of seven subcategories: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The Consensus Sleep Diary is designed to gather information about daily sleep patterns.
Time frame: Day 1 to day 57
Mental wellbeing
Change from baseline to the end of the study period in Mental wellbeing via The World Health Organization-Five Well-Being Index (WHO-5). The WHO-5 is a self-report instrument measuring mental well-being. It consists of five statements relating to the past two weeks. Each statement is rated on a 6-point scale, with higher scores indicating better mental well-being. A score ≤ 50 (or \< 13 in the raw score) is associated with poor well-being or psychological distress and a score ≤ 28 may denote possible clinical symptoms of depression.
Time frame: Day 1 to day 57
Mood
Change from baseline to the end of the study period in Mood via Profile of mood states (POMS). The POMS is a self-reported questionnaire consisting of 65 items, designed to evaluate individuals within seven different mood domains: fatigue-inertia, anger-hostility, vigor-activity, confusion-bewilderment, depression-dejection, tension-anxiety, and friendliness.
Time frame: Day 1 to day 57
Sleep duration
Change from baseline to the end of the study period in Sleep duration via PSQI and Consensus Sleep Diary. The PSQI is a self-report questionnaire used to evaluate overall sleep quality. Each of the 19 items belongs to one of seven subcategories: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The Consensus Sleep Diary is designed to gather information about daily sleep patterns.
Time frame: Day 1 to day 57
Sleep onset latency
Change from baseline to the end of the study period in Sleep onset latency as measured by duration of time (minutes) from turning light off to falling asleep (PSQI and Consensus Sleep Diary). The PSQI is a self-report questionnaire used to evaluate overall sleep quality. Each of the 19 items belongs to one of seven subcategories: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The Consensus Sleep Diary is designed to gather information about daily sleep patterns.
Time frame: Day 1 to day 57
Sleep efficiency
Change from baseline to the end of the study period in Sleep efficiency as measured by ratio of total sleep time to time in bed (PSQI). The PSQI is a self-report questionnaire used to evaluate overall sleep quality. Each of the 19 items belongs to one of seven subcategories: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.
Time frame: Day 1 to day 57
Daytime sleepiness
Change from baseline to the end of the study period in Daytime sleepiness via Functional Outcomes of Sleep Questionnaire (FOSQ-10). The FOSQ-10 consists of 10 items distributed among 5 subscales i.e. general productivity (2 item), activity level (3 items), vigilance (3 items), social outcomes (1 item) and sexual relationship (1 item). Items are rated on a scale of 1-4 (1 = extreme difficulty, 2 = moderate difficulty, 3 = a little difficulty, 4 = no difficulty). The total score is the sum of the 5 sub scores.
Time frame: Day 1 to day 57
Eating in response to experienced stress
Change from baseline to the end of the study period in Eating in response to experienced stress via the Salzburg Stress Eating Scale (SSES). The SSES is a questionnaire use to measure eating in response to experienced stress. The response categories range from 'I eat much less than usual' to 'I eat much more than usual' and are scored on a 5-point Likert scale, i.e., a score from 1 - 5. Higher scores indicate that the respondent eats more when stressed is experienced.
Time frame: Day 1 to day 57
Serotonin
Change from baseline to the end of the study period in serotonin via saliva test.
Time frame: Day 1 to day 57
Cortisol
Change from baseline to the end of the study period in cortisol via saliva test.
Time frame: Day 1 to day 57
Melatonin
Change from baseline to the end of the study period in melatonin via saliva test.
Time frame: Day 1 to day 57
Safety via AE monitoring
Change from baseline to the end of the study period in Safety via AE monitoring
Time frame: Day 1 to day 57
Safety via vital signs (blood pressure)
Change from baseline to the end of the study period in safety via vital signs (blood pressure).
Time frame: Day 1 to day 57
Safety via vital signs (heart rate)
Change from baseline to the end of the study period in safety via vital signs (heart rate).
Time frame: Day 1 to day 57
Safety via vital signs (O2 saturation)
Change from baseline to the end of the study period in safety via vital signs (O2 saturation).
Time frame: Day 1 to day 57
Safety via vital signs (temperature)
Change from baseline to the end of the study period in safety via vital signs (temperature).
Time frame: Day 1 to day 57
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.
Of 14 phase 2 interventional studies under Sleep Wake Disorders, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 57. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lavender oil · Palmidrol · N-oleoylethanolamine